diation therapy, and SRS, alone or in combination. The use of various procedures may be the result of planned staging, or procedures may be used in combination as a salvage treatment after recurrence or progression. This study examines the longer-term benefits and risks of SRS for glomus tumor patients, either as a de novo management or after initial surgery or radiation therapy.
Methods
The data for this study were analyzed in terms of patient procedures. There were 134 procedures performed in 132 patients. Each procedure was analyzed separately.
Patient Selection
Eight medical centers affiliated with the NAGKC received individual institutional review board approval to submit the retrospective clinical outcome analysis of their experience with glomus tumors. The following centers participated: the Mayo Clinic (59 patients), the Barrow Neurological Institute (19 patients), the University of Pittsburgh (18 patients), the University of Virginia (15 patients), the University of Manitoba (6 patients), the University of Sherbrooke (5 patients), Hoag Memorial Hospital (5 patients), and the University of Kentucky (5 patients). The records of glomus tumor patients who underwent GK SRS between 1988 and 2010 were assessed by each center for inclusion (Table 1 ).
An Excel spreadsheet database with selected variables was created and sent to all participating centers. At each participating center, the patients' medical records were reviewed, and the data were entered in the spreadsheet without any patient identifiers. The data were deidentified and sent to an independent third party who confirmed regulatory compliance before sending the data to the first author (J.P.S.), who drafted this assessment on behalf of the NAGKC. Clinical and imaging outcomes were assessed at a median follow-up period of 50.5 months (range 5-220 months) after SRS.
Clinical Material
The total clinical series included 84 women (63%) and 50 men (37%) ( Table 1) . Each patient had only 1 tumor; 70 tumors were on the right side, and 64 were on the left side. The median age of the patients at the time of GKS was 59 years (range 18-88 years) ( Table 2) . Fifty-three patients (39.6%) had initial subtotal surgical removal and therefore had histological confirmation of the tumor. Those without a histological diagnosis were classified as having had a glomus tumor on the basis of clinical presentation and imaging features (for example, location, MRI and/or CT characteristics, and growth behavior). Six patients (4.5%) previously underwent external beam fractionated radiation therapy and had additional tumor progression. The median total dose of prior radiation therapy was 56 Gy (range 18-79 Gy). One patient underwent volume-staged radiosurgical treatment for a larger glomus tumor. Another patient underwent repeat radiosurgery after the tumor progressed despite a prior radiosurgery procedure.
Tumors were classified using both the GlasscockJackson grade and the Fisch type. 16, 27 The distribution of tumors by Glasscock-Jackson grade was as follows: Grade 1 (small tumor involving the jugular bulb, middle ear, and mastoid), 44 cases (33%); Grade 2 (tumor extending under the internal auditory canal), 32 (24%); Grade 3 (tumor extending into petrous apex), 33 (25%); and Grade 4 (tumor extending beyond the petrous apex into the clivus or infratemporal fossa), 24 (18%). 16 The distribution of tumors by Fisch type was as follows: Type A (tumor limited to the middle ear cleft), 3 cases (2%); Type B (tumor limited to the tympanomastoid area), 9 (7%); Type C (tumor involving the infralabryinthine compartment of the temporal bone and extending into the petrous apex), 69 (52%); and Type D (tumor with intracranial extension), 47 (35%) ( Table 1) . 27 All patients were assessed serially by repeat clinical evaluations that recorded response of tinnitus (when present) and the status of cranial nerve function. Postradiosurgical tinnitus was classified as improved, stable, or worsened compared with the patient's preoperative state. Follow-up cranial nerve testing was rated as improved, stable, or worse.
Radiosurgical Procedure
Model U, B, C, 4C, or Perfexion GK units were used, depending on the technology available and time of treatment at participating centers. In general, the procedure began with the application of the Leksell Model G stereotactic frame (Elekta Inc.) under brief anesthesia. After frame application, high-resolution, stereotactic MRI was performed. Thin-sliced MR images were obtained after paramagnetic contrast administration. Stereotactic radiosurgery dose planning was then performed by a team comprising a neurosurgeon, a radiation oncologist, and a medical physicist.
The median tumor volume was 5.5 cm 3 (range 0.6-58.6 cm 3 ). A median of 9 isocenters (range 1-20) was used for dose planning. The median prescription dose delivered to the tumor margin was 15 Gy (range 10-18 Gy). The maximum dose varied from 14 to 50 Gy (median 30 Gy) ( Table 2) .
Evaluation Criteria
Clinical and MRI evaluations were typically performed at intervals of 3-6 months in the 1st or 2nd year after radiosurgery. In patients with continued evidence of tumor growth control and absence of new neurological findings, imaging follow-up intervals increased to 1-2 years. The follow-up MR images were compared with the intraoperative images, and tumor dimensions were measured in the axial, sagittal, and coronal planes. A volume was then roughly calculated by multiplying the left-right (X), anterior-posterior (Y), and superior-inferior (Z) dimensions and dividing this number by 2. Tumor growth within the prescribed isodose volume or adjacent to it was considered tumor progression.
For statistical analysis, we constructed Kaplan-Meier plots for survival and progression-free survival using the dates of diagnosis, first SRS, follow-up MRI studies, and death or last follow-up. Progression-free survival and overall survival time were calculated from the day of the first SRS using the Kaplan-Meier method. Univariate analysis was performed on the Kaplan-Meier curves using log-rank statistics with p < 0.05 set as significant. Prognostic factor variables with p values less than 0.2 on univariate analysis underwent multivariate analysis using a Cox proportional hazard regression model. We performed multivariate analysis using the Cox proportional hazard model, with p < 0.05 set as significant. Standard statistical processing software (SPSS version 17.0, SPSS, Inc.) was used. 
Results

Tumor Response
The median duration of follow-up after GKS was 50.5 months. Follow-up imaging studies were not available in 11 patients. At last follow-up, 114 of 123 evaluable tumors either demonstrated no change in tumor volume (no growth, 65 tumors) or volume reduction (49 tumors). Thus, the overall tumor control was 93%. Actuarial tumor progression-free survival was 98%, 90%, and 88% at 1, 3, and 5 years, respectively (Fig. 1 ). In patients who had upfront radiosurgery (83 patients), the actuarial tumor progression-free survival was 97% at 1 year, 89% at 3 years, and 86% at 5 years post-GKS. For those undergoing salvage radiosurgery after at least 1 resection (51 patients), the actuarial tumor progression-free survival was 98% at 1 year, 93% at 3 years, and 90% at 5 years post-GKS. There was no difference in terms of progression-free survival between those undergoing upfront versus salvage radiosurgery (log-rank test, p > 0.05; Fig. 2 ).
Progression-free survival was evaluated using the Glasscock-Jackson grade (Fig. 3) . However, we could find no difference in progression-free survival between the various Glasscock-Jackson grades (log-rank test, p > 0.05; Fig. 3 ). Similarly, we found no statistically significant difference in progression-free survival using the Fisch staging system (Fisch type).
Age at the time of GKS, histological confirmation, number of isocenters, margin dose (≥ 15 vs < 15 Gy), maximum dose, Fisch type, sex, side of the tumor, tumor volume at the time of GKS, preoperative trigeminal nerve dysfunction, worsened cranial nerve function at last follow-up, and prior resection were statistically evaluated with regard to progression-free survival (Tables 3 and 4) . Univariate analysis showed that the number of isocenters (p = 0.026), trigeminal nerve (CN V) dysfunction prior to GKS (p = 0.020), age at GKS (p = 0.031), and stable or improved cranial nerve function at last follow-up (p = 0.002) were significantly correlated with progressionfree survival (Table 3) . In multivariate analysis, absence of preoperative trigeminal nerve dysfunction (p = 0.001), greater number of isocenters (p = 0.005), and stable or improved cranial nerve function at last follow-up (p = 0.002) correlated with progression-free survival (Table 4) .
Clinical Response
Prior to radiosurgery, the following cranial nerve deficits were noted: CN V in 15 patients (11%); CN VI in 6 (4.5%); CN VII in 33 (25%); CN VIII in 91 (68%); CN IX in 44 (33%); CN X in 62 (46%); CN XI in 27 (20%); and CN XII in 47 (35%). Many patients had more than one cranial nerve deficit. At last follow-up, 20 patients (15%) had some worsening of a preexisting cranial nerve deficit or developed a new deficit (Table 5) . Of interest, only 5 of the patients with new cranial nerve findings demonstrated tumor progression. Fifteen patients (11%) showed improvement in preexisting cranial nerve deficits following radiosurgery, and 99 patients (74%) had no change in cranial nerve function.
Of those patients treated with upfront radiosurgery, 18% developed new or worsened cranial nerve deficits. Of those who underwent salvage radiosurgery after an initial resection, 14% developed new cranial nerve deficits. There was no significant difference in cranial nerve deficits postradiosurgery in those patients treated with upfront radiosurgery compared with those treated with radiosurgery as salvage therapy (chi-square test, p = 0.531).
At the time of GKS, 53 patients (40%) reported tinnitus. After radiosurgery, tinnitus improved in 26 (49%) of these patients. New tinnitus developed in only 1 patient (0.8%) after radiosurgery. No correlation was observed between progression-free survival and tinnitus at either presentation or last follow-up.
At last follow-up, 91% of patients were alive. The actuarial 5-year survival was 94% (Fig. 4) . No patient died of disease progression or treatment-related side effects. The etiologies of the observed deaths included cancer, cardiovascular disease, and stroke.
Adverse Radiation Effects
In the 134 patients, no evidence of malignant transformation of the tumor or radiation-induced neoplasia was noted. Of the 15 patients (11%) with worsening cranial nerve function despite radiological evidence of tumor control, radiosurgery may have been responsible for this neurological decline.
Discussion
Because glomus tumors are relatively rarely encountered even at large medical centers, no consistent treatment algorithm has been developed among treating specialists in neurosurgery, otolaryngology, and radiation oncology. In addition to conservative management, skull base surgery, radiation therapy, and SRS have all been used. The low occurrence rate of these tumors, the variability in neurological symptoms at presentation, and the diverse treatment options available have previously prevented the undertaking of well-designed, multicenter studies to rigorously define an optimal management strategy for patients with glomus tumors.
Recent advances in skull base surgery have been based on improvements in surgical instrumentation, neuronavigation, and preoperative embolization. In their 2010 article on a series of 83 patients with jugular foramen tumors (of which 67 were glomus jugulare tumors), Fayad et al. 6 reported that gross-total resection of the tumor was achieved in 81% of cases. New cranial nerve deficits were noted in 18.9% of patients undergoing resection of glomus jugulare tumors. 6 In older microsurgical series, the rate of total resection varied from 83% to 96%. 1, 9, 17, 28, 29, 40, 41 The incidence of postoperative CSF leaks in these series ranged from 3.8% to 33.3%. 1, 9, 17, 28, 29, 40, 41 Rates of new cranial nerve deficits and mortality were as high as 59% and 4.1%, respectively. 1, 9, 17, 28, 29, 40, 41 Results from these series underscore the clinical challenge that these tumors present and the difficulties involved with even skilled microsurgical approaches.
Fractionated external beam radiation therapy has also been used for patients with glomus tumors. Even using more advanced intensity-modulated radiation therapy generated by modern linear accelerators, the planned treatment volume is always larger than the gross tumor volume defined by imaging. Adjacent cranial nerve and critical vascular structures will receive a radiation dose similar to that received by the tumor. For this reason, radiation oncologists often prefer a standard fractionation scheme to reduce risk and to facilitate normal tissue repair. Radiation therapy success rates vary. In a series of 17 patients, Henzel et al. 12 observed that the 5-year actuarial local tumor control was 100%, and no patient sustained severe toxicities (Grade 3 or 4). In a larger series comprising 121 tumors treated with radiation therapy at the University of Florida, the actuarial 10-year local tumor control was 94%.
14 In other radiation therapy series, the local tumor control rates vary from 80% to 100%.
21,30,36
Radiation doses of 4500-5000 cGy in 20-30 fractions are typically used. Although the incidence of severe complications appears low after fractionated radiation therapy, published studies note the risk of headaches, external otitis, hypopituitarism, cranial nerve deficits, mucositis, and radiation-related malignancy.
14,20
Radiosurgical Outcomes
Radiosurgery has been used for the treatment of glomus tumors for more than a decade. However, to date, the radiosurgical series in the literature consist of smaller, single-institution studies (Table 5) . 5, 7, 8, 18, 22, 32, 33, 39 A recent meta-analysis of glomus tumor cases revealed that radiosurgery afforded a local tumor control rate of 95% (95% CI 92%-99%). 15 In a comparison of gross-total resection, subtotal resection, subtotal resection plus radiosurgery, and radiosurgery alone, radiosurgery alone had the lowest rate of CN IX-XI deficits and the lowest rate of tumor progression. 15 The current retrospective study performed under the auspices of the NAGKC represents the largest radiosurgical series to date. Some of the patients included in this series have also been included in previous series. 4, 33, 39 However, each center has added updated follow-up data. All participating centers possess the same radiosurgical technology and adhere to general radiobiological principles appropriate for SRS using this technology. 25 Inherently, such a study has the advantages of improving the statistical power and reducing the narrowness of selection bias in a single center. Disadvantages of this type of retrospective study include heterogeneity in radiosurgical technique, patient selection, and follow-up protocol.
In this series, GKS tumor control was achieved in 93% of patients. The majority of the patients in this series had Fisch Types C and D glomus tumors. Such tumors typically represent a more challenging group from a microsurgical standpoint. Although radiosurgery controlled the vast majority of glomus tumors treated in this series, we do recommend long-term radiological and neurological follow-up. However, the same recommendations would be made for patients undergoing microsurgical resection or external beam radiotherapy.
Radiosurgery afforded an improvement in tinnitus in nearly one-half of affected patients. Twenty-five percent of patients with new or worsened cranial nerve deficits demonstrated tumor progression on follow-up neuroimaging studies. The development of a new or worsening cranial nerve deficit was a good predictor of delayed tumor growth despite GKS. The presence of trigeminal nerve dysfunction at the time of GKS also correlated with a greater likelihood of tumor progression. Trigeminal nerve dysfunction in patients with glomus tumors was likely an indication of a larger-volume, more extensive tumor. Patients with trigeminal nerve dysfunction prior to radiosurgery may warrant consideration for cytoreductive surgery followed by SRS.
The current study evaluates the outcomes of GKS in patients with glomus tumors. In fact, the vast majority of published radiosurgical series of glomus tumor cases have been from GK centers (Table 5) . Nevertheless, the efficacy of radiosurgery for glomus tumor patients does not appear limited to GK technology. In a 2009 article reporting on a series of 34 patients with large (defined as > 15 cm 3 ) skull base tumors and including some glomus tumor patients, Tuniz et al. 37 demonstrated local tumor control in all patients and 21% clinical improvement after multisession CyberKnife radiation. In another series of 9 patients (8 had glomus jugulare tumors), CyberKnife radiation demonstrated local tumor control in all patients.
3
Indications and Considerations for SRS
At presentation, the patient's signs and symptoms, age, and comorbidities if any, as well as the tumor volume, imaging characteristics, and rate of tumor growth (if able to be determined), should be considered in determining whether radiosurgery is the optimal initial treatment. For young patients with large tumors and significant associated mass effect, resection with or without preoperative embolization affords a chance of a "cure." Similarly, for those with high rates of circulating catecholamines secreted from the tumor, cytoreductive resection may prove useful in rapid improvement of hormonal overproduction. However, one must be cognizant of the limitations of skull base surgery. Professor Robert Ojemann once wrote "If the patient has a high probability of being cured of the tumor or of having a useful life significantly lengthened or more serious disabilities relieved, then the loss of facial nerve function and hearing is acceptable. On the other hand, the loss of ninth and 10th cranial nerve function is one of the most serious neurological disabilities for a patient." 26 If resection is attempted, complete resection is not necessarily the best goal. If cranial nerve injury is likely, subtotal resection followed by SRS would seem a better approach.
Patients with signs and symptoms typical of a glomus tumor and possessing small-to moderate-volume tumors (volume < 15 cm 3 ) with typical imaging features appear to be very good candidates for upfront radiosurgery. The expanded reach of most contemporary radiosurgical platforms (for example, the GK Perfexion) permits radiosurgical delivery to the extracranial (cervical component of the tumor, at least to an inferior component of approximately the C-3 level). Multisession radiosurgery also may allow for an expansion of the radiosurgical approach of favorable local control of larger tumors while still offering a favorable safety profile. 37 Such an approach, however, needs to be more rigorously studied.
Stereotactic radiosurgery appears to be safe and effective for many patients with glomus tumors. Most of these tumors are slow-growing neoplasms that respond well to radiosurgery. Radiosurgical doses (12-15 Gy, comparable to other benign, slow-growing skull base tumors) confer a high rate of local tumor control for patients with glomus tumors. In a recent analysis from the University of Virginia, a margin dose of 13 Gy or greater appeared to confer a higher rate of tumor control with minimal morbidity in a series of 15 patients with glomus tumors. 4 In the current series, the same relationship between dose and long-term tumor control was not observed. Nevertheless, in the absence of tumor growth, cranial nerve injury following radiosurgery to a glomus tumor appears rare at margin doses of 12-15 Gy. Tumor regression can, at times, be associated with improvement of cranial nerve function as demonstrated in 11% of patients in the current series. In addition, we recommend a dose plan that is as conformal as possible to the 3D shape of the tumor and respects dose constraints of adjacent neural and vascular structures at risk.
While radiation therapy confers a reasonable rate of tumor control, radiosurgery appears to offer at least a comparable rate but without the risks inherent with fractionated approaches. No case of radiosurgery-induced neoplasia was observed in this series or reported in the literature following SRS of glomus tumor patients. This is in sharp contrast to the documented 2% risk of neoplasia following fractionated radiotherapy. 24, 31 After radiosurgery, it is important for patients with glomus tumors to undergo serial long-term follow-up. This should include neuroimaging studies and clinical evaluations with detailed neurological examination. It is essential to determine the difference between the natural history of a slow-growing tumor such as a glomus tumor and true radiosurgery-induced tumor control. In past experience with other skull base tumors, patients with longer follow-up have demonstrated either tumor growth or tumor shrinkage. 23 Growth after radiosurgery-induced tumor shrinkage appears rare. Latent adverse effects of radiosurgery have been reported more than 10 years after treatment. 34 Hence, close follow-up of patients treated with radiosurgery should be performed in much the same 
Conclusions
This study, the largest radiosurgical series of cases of glomus tumors to date, shows that GK SRS affords a high rate of local tumor control and a low risk of neurological injury for patients with these tumors. Stereotactic radiosurgery can be used as an upfront treatment or as a salvage treatment for those with recurrent or residual tumor following resection. As for patients undergoing resection or radiotherapy, long-term follow-up is advised for glomus tumor patients undergoing radiosurgery. 
